SCHEMBL13763906

SCHEMBL13763906

CC(=O)NCc1cccc(Nc2ncc3nnn(-c4cccc(CNC(C)=O)c4)c3n2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3A P49840 6/20 0.55
▸ GSK3B P49841 6/20 0.55
▸ AURKA O14965 4/20 0.54
▸ BRD4 O60885 1/20 0.47
▸ SYK P43405 2/20 0.46
▸ EGFR P00533 2/20 0.44
▸ BTK Q06187 1/20 0.44
▸ EIF2AK4 Q9P2K8 2/20 0.44
▸ PTK2 Q05397 2/20 0.42
▸ FLT3 P36888 2/20 0.42
▸ BLK P51451 1/20 0.42
▸ MAP3K5 Q99683 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ USP2 O75604 2/20 0.40
▸ CYP1A2 P05177 2/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ KMT2A Q03164 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13763910 0.96 GSK3A (0.52) GSK3AGSK3BAURKABRD4SYK
SCHEMBL13303700 0.95 GSK3A (0.63) GSK3AGSK3BAURKABRD4SYK
SCHEMBL13763857 0.95 GSK3A (0.63) GSK3AGSK3BAURKABRD4SYK
SCHEMBL13763961 0.95 GSK3A (0.51) GSK3AGSK3BAURKABRD4SYK
SCHEMBL13763908 0.94 GSK3A (0.52) GSK3AGSK3BAURKABRD4SYK
SCHEMBL13763880 0.94 GSK3A (0.51) GSK3AGSK3BAURKABRD4SYK
SCHEMBL13763911 0.94 GSK3A (0.52) GSK3AGSK3BAURKABRD4SYK
SCHEMBL13763861 0.94 GSK3A (0.51) GSK3AGSK3BAURKABRD4SYK
SCHEMBL13763928 0.93 AURKA (0.58) GSK3AGSK3BAURKABRD4SYK
SCHEMBL8296998 0.93 GSK3A (0.58) GSK3AGSK3BAURKABRD4SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560458-B2 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2009-07-14 — — US disclosed
US-7560458-B2 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2009-07-14 — — US disclosed
US-20090036471-A1 Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors EDGARD EDDY JEAN 2009-02-05 — — US disclosed
US-20090036471-A1 Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors EDGARD EDDY JEAN 2009-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036471-A1 Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors GSK3B, GSK3A, GYS2 GSK3A 2/4885GSK3B 1/4885AURKA 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback